We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

79 hedge funds and large institutions have $225M invested in Karyopharm Therapeutics in 2016 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

310% more call options, than puts

Call options by funds: $762K | Put options by funds: $186K

67% more capital invested

Capital invested by funds: $135M → $225M (+$90.4M)

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

53% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 19

5% more funds holding

Funds holding: 75 → 79 (+4)

Holders
79
Holders Change
+4
Holders Change %
+5.33%
% of All Funds
2.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
29
Reduced
19
Closed
7
Calls
$762K
Puts
$186K
Net Calls
+$576K
Net Calls Change
+$442K

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$22.2M
2
Millennium Management
Millennium Management
New York
+$1.26M
3
CS
Candriam SCA
Luxembourg
+$881K
4
BFA
BlackRock Fund Advisors
California
+$621K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$522K

Top Sellers

Rank Fund Capital Flow
1
NLVP
New Leaf Venture Partners
New York
-$1.5M
2
PAI
Palo Alto Investors
California
-$429K
3
TC
TFS Capital
Pennsylvania
-$335K
4
SIP
Stoneridge Investment Partners
Pennsylvania
-$133K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$110K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$446K -$92.1K -766 -20%
TG
27
TCW Group
California
$396K -$8.05K -67 -2%
Jacobs Levy Equity Management
28
Jacobs Levy Equity Management
New Jersey
$388K +$28.8K +240 +10%
Swiss National Bank
29
Swiss National Bank
Switzerland
$359K – – –
New York State Common Retirement Fund
30
New York State Common Retirement Fund
New York
$357K -$2.16K -18 -0.7%
TA
31
Teachers Advisors
New York
$350K – – –
AllianceBernstein
32
AllianceBernstein
Tennessee
$340K – – –
VEA
33
Virtus ETF Advisers
New York
$298K – – –
Citadel Advisors
34
Citadel Advisors
Florida
$286K +$235K +1,957 New
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$275K +$226K +1,881 New
VKH
36
Virtu KCG Holdings
New York
$265K +$218K +1,814 New
ProShare Advisors
37
ProShare Advisors
Maryland
$244K -$37K -308 -16%
CS
38
Credit Suisse
Switzerland
$242K +$38.9K +324 +24%
FAAS
39
First Allied Advisory Services
California
$203K +$167K +1,390 New
Arrowstreet Capital
40
Arrowstreet Capital
Massachusetts
$201K +$166K +1,379 New
PPA
41
Parametric Portfolio Associates
Washington
$194K +$160K +1,328 New
MLICM
42
Metropolitan Life Insurance Company (MetLife)
New York
$189K -$6.01K -50 -4%
HCM
43
Highbridge Capital Management
New York
$188K -$85.2K -709 -36%
Morgan Stanley
44
Morgan Stanley
New York
$175K +$102K +848 +247%
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$162K -$2.76K -23 -2%
Bank of Montreal
46
Bank of Montreal
Ontario, Canada
$159K +$131K +1,088 New
Tudor Investment Corp
47
Tudor Investment Corp
Connecticut
$159K +$131K +1,088 New
EWM
48
Endurance Wealth Management
Rhode Island
$156K +$80.2K +667 +167%
SIP
49
Stoneridge Investment Partners
Pennsylvania
$154K -$133K -1,109 -51%
NFA
50
Nationwide Fund Advisors
Ohio
$150K -$47.1K -392 -28%
1
2
3 4

KPTI Hedge Fund Activity: Q3 2016 in Review

79 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2016, worth a combined $225M — up 67% from $135M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new KPTI positions and 7 closed out — a net gain of 4 holders — while 29 added to existing stakes and 19 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $22.2M. The largest seller was New Leaf Venture Partners, exiting entirely with an estimated $1.5M sold.

  • 79 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2016, up from 75 in Q2 2016.
  • Funds reported $225M of Karyopharm Therapeutics stock for Q3 2016, up 67% quarter-over-quarter.
  • 11 funds opened new Karyopharm Therapeutics positions in Q3 2016 and 7 closed out, a net change of +4 holders.
  • The largest Karyopharm Therapeutics buyer in Q3 2016 was Wellington Management Group, an estimated $22.2M added.
  • The largest Karyopharm Therapeutics seller in Q3 2016 was New Leaf Venture Partners, an estimated $1.5M sold.

Based on aggregated 13F filings for Q3 2016.